Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.

ABSTRACT: Immune checkpoint blockade (CPB) improves melanoma outcomes, but many patients still do not respond. Tumor mutational burden (TMB) and tumor-infiltrating T cells are associated with response, and integrative models improve survival prediction. However, integrating immune/tumor-intrinsic features using data from a single assay (DNA/RNA) remains underexplored. Here, we analyze whole-exome and bulk RNA sequencing of tumors from new and published cohorts of 189 and 178 patients with melanoma receiving CPB, respectively. Using DNA, we calculate T cell and B cell burdens (TCB/BCB) from rearranged TCR/Ig sequences and find that patients with TMB^high and TCB^high or BCB^high have improved outcomes compared to other patients. By combining pairs of immune- and tumor-ex

SUBMITTER: Freeman SS 

PROVIDER: S-EPMC8861826 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature